ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), has signed an agreement with Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, under which ARIAD has granted STA exclusive rights to commercialize Iclusig (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukaemias. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), stock opened at $7.70 in last session, and closed at $7.60, while the day range of ARIA stock is $7.55 – $7.95. The stock showed a positive weekly performance of 13.26%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares sank 27.42 percent on Wednesday with about 7.8 million shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), stock opened at $5.29, in last session and closed at $4.50, by losing -27.42%. The 52 week range of PGNX is $2.53 – $7.45. Company’s market capitalization is $273.71million.
In a patent interference dispute between Idenix Pharmaceuticals Inc. (NASDAQ:IDIX), and Gilead Sciences Inc’s subsidiary, Gilead Pharmasset LLC., involving certain 2′-methyl-2′-fluoro nucleoside compounds useful in the treatment of hepatitis C virus, the United States Patent and Trademark Office Patent Trial and Appeal Board has ruled in favor of Gilead. Idenix Pharmaceuticals Inc (NASDAQ:IDIX), stock decreased -10.45% and finished the last session at $7.20. The EPS of the stock remained -0.87. Company’s market capitalization is $1.09billion.
January 29, 2014 – Geron Corporation (Nasdaq:GERN) announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Geron also expects to grant the underwriters an option to purchase up to an additional 15% of the shares of common stock offered in the public offering, exercisable for 30 days. Geron Corporation (NASDAQ:GERN), stock opened the session at $4.52, and closed the session at $4.33. The 52 week range of the GERN stock remained $0.98 – $7.79 and the day range was $4.30 – $4.53.
Leave a Reply